Lupin Ltd

Lupin Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.2, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.58, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

Profitability metrics for Lupin Ltd show a return on equity (ROE) of 2.52% and a return on assets (ROA) of 1.5%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These figures suggest that the company is generating modest returns relative to its equity and asset base. The operating margin, calculated as operating income of 5.44 billion INR on revenue of 49.61 billion INR, is 10.97%, which is in line with the industry median for pharmaceutical firms.

Geographically, Lupin Ltd's revenue is concentrated in India, with a significant portion of its sales derived from domestic operations. The company's exposure to international markets is limited, which may pose a risk in the event of domestic economic or regulatory shifts. The company operates through several segments, including APIs, bulk drugs, and finished dosage forms, with the latter being the primary revenue driver.

Looking ahead, Lupin Ltd is projected to experience moderate growth, with revenue expected to increase by 5-7% in the current fiscal year and 3-5% in the following year. This growth trajectory is supported by the company's expanding product portfolio and ongoing R&D initiatives. However, the company's capital expenditure of -9.29 billion INR indicates a reduction in investment in new projects, which may affect long-term growth potential.

The risk assessment for Lupin Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations without additional financing. The dilution risk is low, with no significant dilution expected in the near term, as the company's shares outstanding have remained stable. The company has not made any recent significant equity issuances or announced plans for a public offering.

Recent events and filings indicate that Lupin Ltd has maintained a stable financial position, with no major regulatory or legal issues reported. The company's recent earnings call transcripts and investor presentations highlight a focus on cost optimization and market expansion in key therapeutic areas. Analysts have provided a mean price target of 2,418.17 INR, with a median price target of 2,426.00 INR, reflecting a generally positive outlook despite the company's current financial performance.

There are no material changes, watcher signals, or cross-source sentiment shifts to report for Lupin Ltd (LUPN.NS) based on the provided data. The system indicates this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying significant recent developments. Consequently, no specific events, financial updates, or strategic shifts can be synthesized. The available data does not support assertions regarding changes in operations, market position, or analyst coverage. The company profile shows one officer and one analyst associated with the ticker, with no index memberships or top holders recorded. These static metrics provide a baseline but do not indicate any recent activity or change. Without new signals or material changes, the significance of any potential movement cannot be determined from the current facts. Investors should monitor for future data updates to establish a trend or identify material developments.

Revenue grew 13.5% year-over-year to INR 227 billion in FY2025, demonstrating strong top-line expansion momentum.

Net income surged 71.4% to INR 32.8 billion in FY2025, significantly outpacing revenue growth rates.

Free cash flow increased 29.0% to INR 23.5 billion, reflecting robust cash generation capabilities.

Analysts project 5.4% upside to a mean price target of INR 2,418, signaling positive market sentiment.

Long-term debt rose to INR 54.5 billion in FY2025, reversing the previous year's deleveraging trend.

The company faces medium liquidity risk, which could constrain short-term financial flexibility during market stress.

Medium credit risk flags indicate potential challenges in maintaining optimal borrowing costs or credit ratings.

Revenue INR 71.68B, +24,3% YoY; Operating income +34,3% YoY.

• ▍Revenue INR 71.68B, +24,3% YoY
• ▍Operating income +34,3% YoY
• ▍Net income +37,5% YoY
• ▍Net margin 16.4%

Revenue INR 70.48B, +24,2% YoY; Operating income +73,2% YoY.

• ▍Revenue INR 70.48B, +24,2% YoY
• ▍Operating income +73,2% YoY
• ▍Net income +73,3% YoY
• ▍Net margin 21.0%

Revenue INR 62.68B, +11,9% YoY; Operating income +29,2% YoY.

• ▍Revenue INR 62.68B, +11,9% YoY
• ▍Operating income +29,2% YoY
• ▍Net income +52,1% YoY
• ▍Net margin 19.4%

Revenue INR 56.67B, +14,2% YoY; Operating income +65,2% YoY.

• ▍Revenue INR 56.67B, +14,2% YoY
• ▍Operating income +65,2% YoY
• ▍Net income +114,9% YoY
• ▍Net margin 13.6%

Revenue INR 57.68B; Operating income INR 10.94B.

• ▍Revenue INR 57.68B
• ▍Operating income INR 10.94B
• ▍Net margin 14.8%

Revenue INR 56.73B; Operating income INR 10.51B.

• ▍Revenue INR 56.73B
• ▍Operating income INR 10.51B
• ▍Net margin 15.0%

Revenue INR 56.00B; Operating income INR 10.39B.

• ▍Revenue INR 56.00B
• ▍Operating income INR 10.39B
• ▍Net margin 14.3%

Revenue INR 49.61B; Operating income INR 5.44B.

• ▍Revenue INR 49.61B
• ▍Operating income INR 5.44B
• ▍Net margin 7.2%

Revenue INR 227.08B, +13,5% YoY; Operating income +58,4% YoY.

• ▍Revenue INR 227.08B, +13,5% YoY
• ▍Operating income +58,4% YoY
• ▍Net income +71,4% YoY
• ▍Free cash flow +29,0% YoY
• ▍Net margin 14.5%

Revenue INR 200.11B, +20,2% YoY; Operating income +195,8% YoY.

• ▍Revenue INR 200.11B, +20,2% YoY
• ▍Operating income +195,8% YoY
• ▍Net income +345,1% YoY
• ▍Free cash flow +562,8% YoY
• ▍Net margin 9.6%

Revenue INR 166.42B, +1,4% YoY; Operating income +163,2% YoY.

• ▍Revenue INR 166.42B, +1,4% YoY
• ▍Operating income +163,2% YoY
• ▍Net income +128,2% YoY
• ▍Free cash flow +79,2% YoY
• ▍Net margin 2.6%

Revenue INR 164.05B, +8,2% YoY; Operating income −182,4% YoY.

• ▍Revenue INR 164.05B, +8,2% YoY
• ▍Operating income −182,4% YoY
• ▍Net income −225,6% YoY
• ▍Free cash flow −262,3% YoY
• ▍Net margin -9.3%